Literature DB >> 18846559

The impact of incident methicillin resistant Staphylococcus aureus detection on pulmonary function in cystic fibrosis.

Gregory S Sawicki1, Lawrence Rasouliyan2, David J Pasta2, Warren E Regelmann3, Jeffrey S Wagener4, David A Waltz1,5, Clement L Ren6.   

Abstract

The incidence of methicillin resistant Staphylococcus aureus (MRSA) infection is increasing in cystic fibrosis (CF), but the impact of MRSA detection on clinical outcomes is unclear. Our objective was to determine whether incident detection of MRSA is associated with a change in pulmonary function over time in CF patients. We analyzed data from the Epidemiologic Study of Cystic Fibrosis (ESCF), a prospective observational study of CF patients in North America. Multivariable piecewise linear regression was used to model the impact of incident detection of MRSA on pulmonary function over time, measured by percent predicted forced expiratory volume in one second (FEV(1)% predicted), adjusting for potential confounders. There were 5,090 patients >or=6 years old who were MRSA negative for at least 2 calendar years. Five hundred ninety-three (12%) of these patients acquired MRSA during the years 2001-2003, with detection rates of MRSA during those years rising from 4.4% to 6.9%. MRSA positive patients had a lower FEV(1)% predicted and received more antibiotic and other therapies than patients who remained MRSA negative. After adjusting for antibiotic therapy and other potential confounders, MRSA positive patients also had a higher rate of decline in FEV(1)% predicted both before and after the incident culture, although the rate of FEV(1)% predicted decline did not change significantly after MRSA detection. In conclusion, although MRSA in CF was a marker for more aggressive therapy and may reflect increased disease severity, incident MRSA detection was not associated with a changing rate of FEV(1)% predicted decline. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2008        PMID: 18846559     DOI: 10.1002/ppul.20914

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  20 in total

Review 1.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

2.  Multiple antibiotic-resistant Pseudomonas aeruginosa and lung function decline in patients with cystic fibrosis.

Authors:  Clement L Ren; Michael W Konstan; Ashley Yegin; Lawrence Rasouliyan; Benjamin Trzaskoma; Wayne J Morgan; Warren Regelmann
Journal:  J Cyst Fibros       Date:  2012-03-23       Impact factor: 5.482

3.  Children and young adults with CF in the USA have better lung function compared with the UK.

Authors:  Christopher H Goss; Stephanie J MacNeill; Hebe B Quinton; Bruce C Marshall; Alexander Elbert; Emily A Knapp; Kristofer Petren; Elaine Gunn; Joanne Osmond; Diana Bilton
Journal:  Thorax       Date:  2014-09-25       Impact factor: 9.139

4.  Area Deprivation as a Risk Factor for Methicillin-resistant Staphylococcus aureus Infection in Pediatric Cystic Fibrosis.

Authors:  Gabriela R Oates; William T Harris; Steven M Rowe; George M Solomon; Suranjana Dey; Aowen Zhu; Wynton C Hoover; Hector H Gutierrez
Journal:  Pediatr Infect Dis J       Date:  2019-11       Impact factor: 2.129

Review 5.  How can the cystic fibrosis respiratory microbiome influence our clinical decision-making?

Authors:  Geraint B Rogers; Kenneth D Bruce; Lucas R Hoffman
Journal:  Curr Opin Pulm Med       Date:  2017-11       Impact factor: 3.155

Review 6.  Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic.

Authors:  Michael Z David; Robert S Daum
Journal:  Clin Microbiol Rev       Date:  2010-07       Impact factor: 26.132

7.  Prevalence and clinical associations of Staphylococcus aureus small-colony variant respiratory infection in children with cystic fibrosis (SCVSA): a multicentre, observational study.

Authors:  Daniel J Wolter; Frankline M Onchiri; Julia Emerson; Mimi R Precit; Michael Lee; Sharon McNamara; Laura Nay; Marcella Blackledge; Ahmet Uluer; David M Orenstein; Michelle Mann; Wynton Hoover; Ronald L Gibson; Jane L Burns; Lucas R Hoffman
Journal:  Lancet Respir Med       Date:  2019-11-11       Impact factor: 30.700

8.  Influenza-associated cystic fibrosis pulmonary exacerbations.

Authors:  Justin R Ortiz; Kathleen M Neuzil; John C Victor; Anna Wald; Moira L Aitken; Christopher H Goss
Journal:  Chest       Date:  2009-12-04       Impact factor: 9.410

Review 9.  Measuring and improving respiratory outcomes in cystic fibrosis lung disease: opportunities and challenges to therapy.

Authors:  Edith T Zemanick; J Kirk Harris; Steven Conway; Michael W Konstan; Bruce Marshall; Alexandra L Quittner; George Retsch-Bogart; Lisa Saiman; Frank J Accurso
Journal:  J Cyst Fibros       Date:  2009-10-14       Impact factor: 5.482

Review 10.  Cystic Fibrosis: Microbiology and Host Response.

Authors:  Edith T Zemanick; Lucas R Hoffman
Journal:  Pediatr Clin North Am       Date:  2016-08       Impact factor: 3.278

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.